Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

726966.pdf (2.93 MB)

Document type

Article

Version

Published version

Publication date

2022-06-26

Publication license

cc by-nc-nd (c) Kotmayer, Lili et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/191099

GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1111/bjh.18330

Abstract

The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called 'myeloid neoplasms with germline predisposition'. A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.

Subject

Leucèmia mieloide, Proteïnes, Mutació (Biologia)

Subject (English)

Myeloid leukemia, Proteins, Mutation (Biology)

Citation

Collections

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)

Citation

KOTMAYER, Lili, et al. GATA2 deficiency and MDS/AML: experimental strategies for disease modelling and future therapeutic prospects. British Journal of Haematology. 2022. Vol. 199, num. 4, pags. 482-495. ISSN 0007-1048. [consulted: 7 of August of 2026]. Available at: https://hdl.handle.net/2445/191099

Export metadata

JSON - METS

Share record